Madrigal Pharmaceuticals To Participate In The H.C. Wainwright & Co. 8Th Annual MASH Investor Conference
Date
10/2/2024 8:16:16 AM
(MENAFN- GlobeNewsWire - Nasdaq) CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.
The fireside chat will be webcast live and may be accessed here or by visiting Madrigal's website's Investor Relations Events page . A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit .
Investor Contact
Tina Ventura, ...
Media Contact
Christopher Frates, ...
MENAFN02102024004107003653ID1108739071
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.